BioSpace News Archive

Pomerantz LLP is investigating claims on behalf of investors of Amarin Corporation plc.

Therap has introduced new functionality allowing users to reset their own passwords, designed for occasions when users have become locked out of their accounts or forgotten their password.

Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-Cells prevents monocyte-dependent release of key cytokine release syndrome mediators

Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that Novartis has exercised its option to license AKCEA-APO(a)-LRx, a drug to treat patients with elevated levels of lipoprotein(a), or Lp(a), and established cardiovascular disease (CVD). AKCEA-APO(a)-LRx, referred to by Novartis as TQJ230, was discovered by Ionis and co-developed by Akcea and Ionis.

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Diplomat Pharmacy, Inc. from February 26, 2018 through February 21, 2019, inclusive.

The Gardens at Gettysburg underlines its commitment to dynamic recreational program for its residents

Sage Therapeutics announced the pricing of an underwritten public offering of 3,333,334 shares of its common stock at a public offering price of $150.00 per share.

Santhera Pharmaceuticals (SIX: SANN) announces results from the SYROS study demonstrating that long-term treatment with idebenone consistently reduced the rate of respiratory function loss in patients with Duchenne muscular dystrophy (DMD) for up to 6 years in a real-world setting.

CUBIO Innovation Center started launching new biomedical companies in Houston’s world-renowned Texas Medical Center, kicking off with an incubator competition worth $200,000 in start-up funds.

Therap’s disability software offers tools for targeted case management and managed care for the I/DD and LTSS communities